Statins
Common brand names: Lipitor, Crestor, Zocor, Pravachol
Two nutrients listed against this medication. The most severe is marked critical.
At a glance
One of the two is marked well documented. The other one carries its own evidence level.
At a glance
- CoQ10Critical · Well documented
- Geranylgeraniol (GG)Moderate · Mechanism only, no human trial
Color shows how serious each listed effect is. The label beside it shows how strong the evidence is. The cards below explain each one and show its evidence.
Nutrients it can lower
A prescribing cascade is when the side effect of one drug is read as a new condition and a second product is started to treat it. In 2025 an international panel of experts in geriatric medicine and pharmacology published a list of 65 potentially inappropriate cascades. Three begin with a statin and muscle pain or inflammation: a statin followed by a pain reliever, by a mineral supplement, or by quinine. The panel names no CoQ10 or geranylgeraniol product, and neither is a mineral. A 2026 study of 2.3 million adults aged 66 and over in Ontario measured how often the panel's cascades occur in pharmacy records: 10.9% of people who started a statin were started on a pain reliever afterward, one of the three most frequent sequences the study reports. The study records the order in which prescriptions were filled, not that the statin caused each one, and it did not capture products bought without a prescription.
Rochon et al. (European Geriatric Medicine, 2025; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 40742670): international expert panel's list of 65 potentially inappropriate prescribing cascades. Rochon et al. (BMJ, 2026; PMID 42727946): population-level cohort of 2,297,942 adults aged 66 and over in Ontario, measuring how often the panel's 65 cascades occur; 24 met all three prioritization criteria.
Mechanism, Statins block the mevalonate pathway, which makes both cholesterol and CoQ10. In placebo-controlled trials statins lowered plasma CoQ10, and the fall held for each of the four statins tested: atorvastatin, simvastatin, rosuvastatin and pravastatin. No dose-response was reported, and whether the lower blood level causes muscle symptoms was not tested.
Common signs, Muscle pain (myalgia), fatigue, weakness, exercise intolerance
Folkers et al. (Proc Natl Acad Sci, 1990; PMID 2247468): lovastatin lowered blood CoQ10 in humans. Rundek et al. (Arch Neurol, 2004; PMID 15210526): atorvastatin 80 mg/day roughly halved blood CoQ10 in 34 patients within 30 days. Banach et al. (Pharmacol Res, 2015; PMID 26192349): meta-analysis A study that pools the numbers from several trials into one combined estimate. of 8 placebo-controlled trial arms; plasma CoQ10 fell on atorvastatin, simvastatin, rosuvastatin and pravastatin alike, with no difference between lipophilic and hydrophilic statins; the authors call the clinical relevance unclear.
CoQ10 was used at 200 to 400 mg daily. Note which form: the heart-failure outcome evidence (Q-SYMBIO, Grade B) used ubiquinone, not ubiquinol, and this site does not claim one form outperforms the other.
Mechanism, Statins inhibit HMG-CoA reductase, blocking the mevalonate pathway. That pathway produces cholesterol and CoQ10 and also geranylgeraniol (GG), which is required for prenylation of the small GTPases that skeletal muscle cells depend on. The biochemical block is established. Whether GG depletion contributes to statin-associated muscle symptoms in people has not been established: no trial has measured a GG deficit in symptomatic patients, and the primary human efficacy trial is ongoing.
Common signs, Muscle pain (myalgia), weakness, exercise intolerance, same presentation as CoQ10 depletion but often persists after CoQ10 replacement alone.
Osaki et al. (Molecular Metabolism, 2026; PMID 42323079): skeletal muscle-specific loss of Rab geranylgeranyl transferase produces the myopathy phenotype, which is the mechanistic basis for the proposal. The supporting work is animal and cell culture only, cited in full on the geranylgeraniol page. No human trial has measured a GG deficit or shown that repletion relieves symptoms.
No human trial has tested whether supplemental geranylgeraniol relieves statin-associated muscle symptoms, so there is no studied human dose to report and no human evidence of benefit to weigh. The mevalonate-pathway rationale is biochemically established; the clinical question is open, and the primary human efficacy trial is ongoing. Geranylgeraniol is graded D on this basis.
For your next appointment
It prints or saves as a single page. Whether to add a supplement for a nutrient this medication may lower is a decision for your prescriber.
Disclosure
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →